Mucopolysaccharidosis III, Gene Mutation Panel
Mucopolysaccharidosis type III (MPS III) is an autosomal recessive, lysosomal storage disease caused by biallelic mutations in one of four genes that encode for lysosomal enzymes required for the degradation of heparan sulfate and other glycosaminoglycans (GAGs). Mutations in either SGSH (MPS IIIA), NAGLU (MPS IIIB), HGSNAT (MPS IIIC) or GNS (MPSIIID) result in the accumulation of heparan sulfate within lysosomes and cellular dysfunction. Although, symptoms are similar, MPS III is divided into types IIIA, IIIB, IIIC, and IIID, which are distinguished by their genetic cause. Regardless of the gene involved, MPS III is characterized by progressive central nervous system degeneration resulting in severe intellectual disability (ID), developmental regression, and other neurologic manifestations including autism spectrum disorder (ASD), behavioral problems, and sleep disturbances. The estimated incidence of all four types combined is 1 in 70,000 newborns.
Systemic manifestations of MPS III include musculoskeletal problems (joint stiffness, contractures, scoliosis, and hip dysplasia), hearing loss, respiratory tract and sinopulmonary infections, and cardiac disease (valvular thickening, defects in the cardiac conduction system). Mental abilities may decline as the disease progresses. Death usually occurs in the second or third decade of life secondary to neurologic regression or respiratory tract infections.
- Diagnostic confirmation and subclassification of mucopolysaccharidosis type III
- Carrier screening in family members of an affected patient
- For the prenatal genetic test in an individual at risk of MPS III
- For pre-implantation genetic diagnosis of MPS III
- To assist with prognosis, clinical management and surveillance for disease features based on the genetic variant involved
Negative for mutation or pathogenic variant tested (Negative for mutations analyzed)
Whole blood, Blood spot, skin biopsy, cultured cells.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Mol Genet Metab. 2014;113: 34-41. [PMID: 25127543]
- Pediatr Endocrinol Rev. 2014;12 Suppl 1: 133-40. [PMID: 25345095]
- Ann Neurol. 2010;68: 876-87. [PMID: 21061399]
- J Inherit Metab Dis. 2008;31: 240-52. [PMID: 18392742]
- Pediatrics. 2007;120: e1255-61. [PMID: 17938166]
- Genetics Home Reference. Available: https://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-iii#
- GeneReviews® [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK546574/